(4S,5R)-3-{[(7R)-4-chloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-7-yl]carbonyl}-4-methyl-5-phenyl-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: (4S,5R)-3-{[(7R)-4-chloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-7-yl]carbonyl}-4-methyl-5-phenyl-1,3-oxazolidin-2-one
• 英文别名: (4S,5R)-3-[(7R)-4-chloro-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbonyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one
• 化学式: C₂₁H₁₈ClN₃O₃S
• 分子量: 427.911
• InChiKey: BOGKVEVNKJQCDP-PPHDSNJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (RS)-4-chloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine-7-carboxylic acid 在 正丁基锂 、 氯化亚砜 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 5.0h， 生成 (4S,5R)-3-{[(7S)-4-chloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-7-yl]carbonyl}-4-methyl-5-phenyl-1,3-oxazolidin-2-one 、 (4S,5R)-3-{[(7R)-4-chloro-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-7-yl]carbonyl}-4-methyl-5-phenyl-1,3-oxazolidin-2-one
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLOPYRIDINAMINES
  [FR] PYRAZOLOPYRIDINAMINES SUBSTITUÉES

  摘要：

  本发明涉及一般式(I)所述的取代吡唑吡啶胺化合物，以及制备该化合物的方法，用于制备该化合物的中间化合物，包含该化合物的药物组合物和配方，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增殖、血管生成障碍、炎症性疾病或与炎症性疼痛相关的疾病，作为唯一药物或与其他活性成分组合使用。

  公开号：

  WO2017081003A1

文献信息

• [EN] SUBSTITUTED PYRAZOLO-PYRIDINAMINES<br/>[FR] PYRAZOLO-PYRIDINAMINES SUBSTITUÉES
  申请人：BAYER PHARMA AG

  公开号：WO2015004024A1

  公开（公告）日：2015-01-15

  The present invention relates to substituted pyrazolopyridine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式I所述和定义的取代吡唑吡啶化合物，涉及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和复合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖和/或血管生成紊乱的疾病，作为唯一药剂或与其他活性成分组合使用。
• [EN] THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS<br/>[FR] THIÉNOPYRIMIDINES EN TANT QU'INHIBITEURS DE MKNK1 ET DE MKNK2
  申请人：BAYER PHARMA AG

  公开号：WO2015074986A1

  公开（公告）日：2015-05-28

  The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）所述的取代噻吩嘧啶化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和组合物，以及使用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分结合。
• [EN] SUBSTITUTED THIENOPYRIMIDINES AND PHARMACEUTICAL USE THEREOF<br/>[FR] THIÉNOPYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：BAYER PHARMA AG

  公开号：WO2014118229A1

  公开（公告）日：2014-08-07

  The present invention relates to substituted thienopyrimidine compounds of general formula(I)as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式(I)所述的取代噻吡嘧啶化合物，以及制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的药物组合物和配方，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分结合。
• [EN] BENZOTHIADIAZOLAMINES<br/>[FR] BENZOTHIADIAZOLAMINES
  申请人：BAYER PHARMA AG

  公开号：WO2015181104A1

  公开（公告）日：2015-12-03

  The present invention relates to substituted benzothiadiazolamine compounds of general formula(I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式(I)所述的取代苯并噻二唑胺化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和药物组合物，以及用于制造治疗或预防疾病的药物组合物的用途，特别是用作唯一活性成分或与其他活性成分结合。
• [EN] PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS<br/>[FR] PYRAZOLOPYRIDINAMINES UTILISÉES COMME INHIBITEURS DE MKNK1 ET DE MKNK2
  申请人：BAYER PHARMA AG

  公开号：WO2016096721A1

  公开（公告）日：2016-06-23

  The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）所述的取代吡唑吡啶胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖和/或血管生成紊乱、炎症性疾病和与炎症性疼痛相关的疾病的单一药剂或与其他活性成分组合使用。